Fluoroquinolones for treating tuberculosis (presumed drug-sensitive)
Citation: Ziganshina L.E., Titarenko A.F., Davies G.R. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database of Systematic Reviews 2013, Issue 6. Art. No.: CD004795. DOI: 10.1002/14651858.CD004795.pub4.
Substituting or adding fluoroquinolones to established first‐line antituberculous drug regimens gives no additional benefit or risks.
Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis bacteria. Over two billion people worldwide are believed to be latently infected with TB and approximately 10% of these people will develop active TB later in life. The World Health Organization recommends fluoroquinolones for people with presumed drug-sensitive tuberculosis who cannot take standard first-line drugs. Their use could shorten the length of treatment and improve other outcomes in this population. This review includes research published up to 6 March 2013 and identifies five randomised controlled trials (1330 people) that met the inclusion criteria. No studies examined the effect of including fluoroquinolones in a standard six month TB treatment regimen on treatment failure. It is unknown whether adding fluoroquinolones or substituting fluoroquinolones for ethambutol in a standard six month TB treatment regimen reduces treatment failure, relapse, death, or adverse events. HIV‐positive participants were relatively well‐represented in the included trials but none of the included trials stratified outcomes by HIV status. Also, the primary outcomes of all the included trials were reached before initiation of antiretroviral treatment. Currently, there are nine randomised controlled trials ongoing.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the health of refugees and asylum seekers but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the health of refugees and asylum seekers on the basis of this summary alone.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.